Pulmonary embolism
542 results
201 - 300Age-adjusted D-dimer cutoff levels more accurate for PE diagnosis (ADJUST-PE)
Temporary IVC filter added to anticoagulation does not decrease risk of PE recurrence
Chronic diseases and pregnancy
Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction)
Wells score plus age-adjusted d-dimer rules out more PEs
Increasing the D-dimer threshold for patients with low clinical pretest probability effectively rules out PE (PEGeD)
Guidelines for the clinical diagnosis of VTE (AAFP, ACP)
Aspirin prevents recurrent venous thromboembolism
Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE
Antithrombotic agents in primary health care
Prevention of venous thromboembolism
Acute coronary syndrome
Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy: Cochrane systematic review
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement: Cochrane systematic review
Nephrotic syndrome
Compression stockings for preventing deep vein thrombosis in airline passengers
Diving medicine
Oral rivaroxaban as effective as standard therapy for treatment of acute PE
Menopausal symptoms and hormone therapy
Warfarin therapy
Dyspnoea
Risk of myocardial infarction in users of third generation oral contraceptives
20 mcg versus over 20 mcg estrogen combined oral contraceptives for contraception
Testosterone does not increase major adverse cardiac events, but does increase risk of AFib, PE, acute kidney injury, and arrhythmia (TRAVERSE)
Optimal dosing for thromboprophylaxis in medical inpatients
Fixed-dose, subcutaneous, unfractionated heparin effective for VTE
Thrombolysis for PE reduces rate of all-cause mortality but increases risk of major bleeding
Anaphylaxis
Fondaparinux effective for superficial thrombosis but at very high cost
Thromboembolism recurrence likely; consider it a chronic disease (MARVELOUS)
Enoxaparin better than aspirin for prevention of venous thromboembolism after total hip or knee arthroplasty
Delirium in the elderly
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis
Genotype-guided perioperative warfarin dosing may not be superior to algorithm-guided dosing
Differential diagnostics of episodic symptoms
Prolonged fever in the adult
Low molecular weight heparin in patients with lower-leg immobilization
Dalteparin = unfractionated heparin for ICU DVT prophylaxis
Haemoptysis
Extended anticoagulation may be helpul for patients with unprovoked VTE or PE
Tranexamic acid may reduce bleeding after cesarean delivery, but with a risk of adverse effects
Multidetector CT accurate for PE, but requires clinical context
Clinical rule to identify patients at low risk of recurrent VTE
Fibrinolysis for intermediate-risk PE: increased bleeding, no mortality effect
Heparins and mechanical methods for thromboprophylaxis in colorectal surgery
Chronic heart failure
Third-generation oral contraceptives associated with greater risk of PE, stroke, and MI
Prehospital emergency care
Patients with initial unprovoked DVT or PE benefit from long-term low-dose aspirin (INSPIRE)
Echocardiography as an outpatient procedure
Raynaud's phenomenon (RP) or white finger disease
Anticoagulants for people hospitalised with COVID‐19
Interventions for preventing venous thromboembolism following abdominal aortic surgery
Low-molecular-weight heparins vs. standard heparin for acute ischaemic stroke
IPC safer and as effective as medical prophylaxis; much better than TEDS
Deep vein thrombosis
Warfarin: damned if you do, damned if you don't
Thrombolysis for acute upper extremity deep vein thrombosis
Both upper-extremity and lower-extremity DVT risk increased with PICCs
Catheter ablation for paroxysmal and persistent atrial fibrillation: Cochrane systematic review
Low-risk patients with PE can be treated as outpatients
ACP Guideline: Universal VTE prophylaxis not recommended for hospitalized medical and stroke patients
Dabigatran safe and effective for VTE
Anticoagulation for perioperative thromboprophylaxis in people with cancer
Apixaban slightly more effective and safe than warfarin, but more expensive
No decrease in all-cause mortality with LMWH for VTE prophylaxis in hospitalized medical patients
Anticoagulation for cerebral venous sinus thrombosis: Cochrane systematic review
Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation
Oral anticoagulation for prolonging survival in patients with cancer
Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Low rate of symptomatic VTE after elective knee arthroscopy
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
In-flight medical emergencies
Acute abdomen in the adult
Topical application of tranexamic acid for the reduction of bleeding
Combined oral contraceptives: venous thrombosis: Cochrane systematic review
Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction): Cochrane systematic review
Tranexamic acid for reducing mortality in emergency and urgent surgery
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy
Dabigatran versus LMWHs for thromboprophylaxis after total hip or knee replacement
Obesity not associated with adverse hip replacement outcomes